Usage of Oplusituzumab/Ointuzumab (Besponsa)

Besponsa/Besponsa) is administered by intravenous injection, usually by a medical professional in a medical institution. The initial treatment dose is 1.8 mg/m2 of body surface area, administered intravenously once per cycle. Treatment is usually given in one 28-day cycle and may require multiple cycles, depending on the patient's condition and response to treatment. After initial treatment, patients may need to continue receiving oxinuximab/oxinuximab to maintain leukemia remission. The dosage and frequency of this phase are usually determined by the doctor based on the patient's condition.